Faculty Profile, National Health Research Institutes, Taiwan

Faculty Profiles

Jacqueline Whang-Peng, M.D.

Distinguished Investigator & Acting Director
National Institute of Cancer Research


M.D. Medical College of Taiwan University, Taiwan, 1956


- Director, National Institute of Cancer Research, National Health Research Institutes, Taiwan (2006-September 2007)
- Director, Division of Cancer Research, National Health Research Institutes, Taiwan (1996-2005)
- Professor, Medical College, National Taiwan University (1995-present); National Defense Medical College (1994-present); Institute of Clinical Medicine, National Yang-Ming University, Taiwan (1993-present)
- Director, Cancer Clinical Research Center, Institute of Biomedical Sciences, Academia Sinica, Taiwan (1994-1996)
- Medical Director, Public Health Service, Chief, Cytogenetic Oncology Section, Medicine Branch, Clinical Oncology Program, DCT, National Cancer Institute, USA (1976-1993)


One of Dr. Whang-Peng's research interests is cancer genetics and cytogenetics. She focuses on promotion the basic molecular genetic research, exploration and understanding the basic mechanism of carcinogenesis. She also dedicates to search for novel clinical trials for the locally prevalent cancers: new drugs, biological modifiers and gene therapy.

Whang-Peng's team members hope further improvements will be through translational research to the bedside.


Dr. Whang-Peng is an Academician and Council Member of Academia Sinica, ROC. She has been Director of the National Institute of Cancer Research since 2006. The main goals for this Institute are to establish appropriate therapeutic strategies and ascertain appropriate new drugs suitable for the treatment of locally prevalent cancer patients through locally initiated clinical trials, to integrate the biomedical technology into cancer research and clinical patient management, to establish a national inter-hospital patient management network to promote and integrate multi-center clinical trials, as well as to identify and train future basic and clinical oncology research leaders, physicians and nurses. Under Dr. Whang-Peng's leadership, the Institute of Cancer Research aims for further improvement and management of cancer through research efforts, and to channel research results to the bedside through translation research.

Dr. Whang-Peng obtained her M.D. from College of Medicine, National Taiwan University in 1956. She was Medical Director, Public Health Service and Chief, Cytogenetic Oncology Section, NCI, NIH, USA from 1976 to 1993, and was President of the Chinese Oncology Society and the Chinese Society of Genetics. Dr. Whang-Peng is Professor of National Yang-Ming University, Professor of National Taiwan University, and Honorary Lecturer of National Tsing Hua University. She also serves on the Academic Review Committee, Ministry of Education and Atomic Energy Council, Executive Yuan, and is Vice President of Formosa Cancer Foundation. Dr. Whang-Peng's areas of research are cancer genetics and therapeutics. She has authored more than 365 publications. She is also one the editorial board for several nationally and internationally recongnized journals and is a regular reviewer for many others.


- Councilor, The Central Cancer Control Meeting, Executive Yuan, Taiwan, ROC (2004-present)
- Honorary Lecturer, National Tsing Hua University, Taiwan, ROC (2001 to 2004)
- Member, Atomic Energy Council, Executive Yuan, Taiwan, ROC (1998-present)
- President, The Chinese Society of Clinical Oncology, Taiwan, ROC (1998-2001)
- President, The Chinese Society of Genetics, Taiwan, ROC (1996-1999)
- Special Medical Research Chair, National Science Council, Taiwan, ROC (1993-1995)
- PHS Commendation Award, USA (1989)
- Member of Academia Sinica, Taiwan, ROC (1984)
- Arthur Flemming Award, USA (1971)


- Chen YM, Perng RP, Tsai CM, Whang-Peng J.: A phase II trial of gemcitabine plus UFUR combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy. Lung Cancer, Jun;52(3):333-8, 2006.
- Chen YM, Shih JF, Perng RP, Tsai CM, Whang-Peng J.: A randomized trial of different docetaxel schedules in non-small cell lung cancer patients who failed previous platinum-based chemotherapy. Chest, 129(4):1031-8, 2006.
- Chang HJ, Wang CC, Cheng AL, Hsu C, Lu YS, Chang MC, Lin JT, Wang HP, Liu TW, Chang JY, Whang-Peng J.: Chen LT*. Phase I study of biweekly gemcitabine, oxaliplatin and simplified 48-hr infusion of fluorouracil/leucovorin (GOFL) for advanced pancreatic cancer. J Gastroenterol Hepatol. 21(5);874-9, 2006.
- Shiah HS, Cheng AL, Hsu C, Hsu CH, Liu TW, Chang JY, Jan CM, Chao Y, Yu WL, Chung TR, Whang-Peng J.: Chen LT*. Phase I-II trial of weekly gemcitabine plus high-dose 5-fluorouracil and leucovorin in advanced pancreatic cancer. J Gastroenterol Hepatol. 2006 Mar;21(3):531-6, 2006.
- Shiah HS, Chen LT, Chao Y, Yao TJ, Huang JD, Chang JY, Chen PJ, Chuang TR, Chin YS, Whang-Peng J., Liu TW. Phase I and pharmacokinetic study of oral thalidomide in patients with advanced hepatocellular carcinoma. Cancer Chemother Pharmacol, 58(5):654-664, 2006.
- Chen LT*, Lin JT, Tai JJ, Chen GH, Yeh HZ, Yang SS, Wang HP, Kuo SH, Sheu PS, Jan CM, Wang WM, Wang TE, Wu CW, Chen CL, Su IJ, Whang-Peng J.: Cheng AL*. Long-term results of anti-Helicobacter pylori therapy in early-stage high-grade transformed gastric MALT lymphoma. J Natl Cancer Inst 97(18):1345-1353, 2005.
- Chen YM, Perng RP, Shih JF, Tsai CM, Whang-Peng J.: Chemotherapy for non-small cell lung cancer in elderly patients. Chest. Jul;128(1):132-9, 2005


- US Patent No.11/099,451, Granted April 6, 2005; ROC Patent No.94112042, Granted April 15, 2005; "Simple and rapid derivation of functional hepatocytes from human bone marrow-derived mesenchymal stem cells."